- Home
- GLXG vs BLRX Comparison
GLXG vs BLRX Comparison
Compare GLXG & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLXG
- BLRX
- Stock Information
- Founded
- GLXG 2013
- BLRX 2003
- Country
- GLXG Hong Kong
- BLRX Israel
- Employees
- GLXG N/A
- BLRX N/A
- Industry
- GLXG
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- GLXG
- BLRX Health Care
- Exchange
- GLXG NYSE
- BLRX Nasdaq
- Market Cap
- GLXG 11.1M
- BLRX 12.1M
- IPO Year
- GLXG 2024
- BLRX 2011
- Fundamental
- Price
- GLXG $0.61
- BLRX $3.09
- Analyst Decision
- GLXG
- BLRX Buy
- Analyst Count
- GLXG 0
- BLRX 2
- Target Price
- GLXG N/A
- BLRX $26.00
- AVG Volume (30 Days)
- GLXG 139.7K
- BLRX 15.5K
- Earning Date
- GLXG 05-27-2025
- BLRX 05-27-2025
- Dividend Yield
- GLXG N/A
- BLRX N/A
- EPS Growth
- GLXG N/A
- BLRX N/A
- EPS
- GLXG N/A
- BLRX N/A
- Revenue
- GLXG $3,711,233.00
- BLRX $28,940,000.00
- Revenue This Year
- GLXG N/A
- BLRX N/A
- Revenue Next Year
- GLXG N/A
- BLRX N/A
- P/E Ratio
- GLXG N/A
- BLRX N/A
- Revenue Growth
- GLXG N/A
- BLRX 502.92
- 52 Week Low
- GLXG $0.52
- BLRX $2.30
- 52 Week High
- GLXG $16.93
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- GLXG N/A
- BLRX 47.99
- Support Level
- GLXG N/A
- BLRX $3.01
- Resistance Level
- GLXG N/A
- BLRX $3.25
- Average True Range (ATR)
- GLXG 0.00
- BLRX 0.17
- MACD
- GLXG 0.00
- BLRX -0.01
- Stochastic Oscillator
- GLXG 0.00
- BLRX 17.10
About GLXG GALAXY PAYROLL GROUP LTD
Galaxy Payroll Group Ltd provides payroll outsourcing, employment, consultancy, and market research services based in Hong Kong. Its client base includes retail, trading, industrial, IT, financial, and professional services industries. Geographically, the company derives maximum revenue from its clients in the People's Republic of China and the rest from Hong Kong, Macau, Taiwan, Japan, Thailand, Singapore, and other countries.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.